![Hui Ju Chan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Hui Ju Chan
Directeur/Membre du Conseil chez
PHARMADAX INC.
Profil
Hui Ju Chan currently works at PharmaDax (Guangzhou), Inc., as Chairman, Empax Pharma (Foshan) Inc., as Chairman, PharmaDax Inc., as Director, PharmaDax USA, Inc., as Director, Sandex Group Ltd., as Director, Fortune Tower Group Corp., as Director, and Shengqun Pharmaceutical Co., Ltd., as Director.
Ms. Chan received her undergraduate degree from National Taipei University of Technology and Masters Business Admin degree from Soochow University.
Postes actifs de Hui Ju Chan
| Sociétés | Poste | Début |
|---|---|---|
| PHARMADAX INC. | Directeur/Membre du Conseil | - |
PharmaDax (Guangzhou), Inc. | Président | - |
PharmaDax USA, Inc.
 PharmaDax USA, Inc. Pharmaceuticals: MajorHealth Technology The company is located in the US. Part of PharmaDax Inc., PharmaDax USA, Inc. is an American pharmaceutical company specializing in the development, manufacturing, and marketing of generic and specialty modified-release oral solid dosage drugs. The company focuses on complex sustained-release formulations primarily in central nervous system (CNS) and cardiovascular system (CVS) therapeutic areas. PharmaDax operates two GMP-compliant manufacturing facilities with a combined tablet production capacity of 600 million units annually, expandable to 1.5 billion, and employs around 230 team members across five countries. Its proprietary technology platforms include non-erosive adjustable drug delivery systems, modified-release orally disintegrating tablets, sustained-release gastro-retentive dosage forms, and transdermal patches. PharmaDax has received FDA approvals for generic versions of drugs such as glyburide, quetiapine fumarate ER, and metoprolol succinate ER, and offers co-development, marketing partnerships, dossier development, technology transfer, and contract development and manufacturing services. | Directeur/Membre du Conseil | - |
Sandex Group Ltd. | Directeur/Membre du Conseil | - |
Fortune Tower Group Corp. | Directeur/Membre du Conseil | - |
Empax Pharma (Foshan) Inc. | Président | - |
Shengqun Pharmaceutical Co., Ltd. | Directeur/Membre du Conseil | - |
Formation de Hui Ju Chan
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
11
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
National Taipei University of Technology
 National Taipei University of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Soochow University /Taiwan/
 Soochow University /Taiwan/ Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
PharmaDax Inc.
 PharmaDax Inc. Pharmaceuticals: MajorHealth Technology Manufactures, develops and markets pharmaceutical products | Health Technology |
PharmaDax USA, Inc.
PharmaDax USA, Inc. Pharmaceuticals: MajorHealth Technology The company is located in the US. Part of PharmaDax Inc., PharmaDax USA, Inc. is an American pharmaceutical company specializing in the development, manufacturing, and marketing of generic and specialty modified-release oral solid dosage drugs. The company focuses on complex sustained-release formulations primarily in central nervous system (CNS) and cardiovascular system (CVS) therapeutic areas. PharmaDax operates two GMP-compliant manufacturing facilities with a combined tablet production capacity of 600 million units annually, expandable to 1.5 billion, and employs around 230 team members across five countries. Its proprietary technology platforms include non-erosive adjustable drug delivery systems, modified-release orally disintegrating tablets, sustained-release gastro-retentive dosage forms, and transdermal patches. PharmaDax has received FDA approvals for generic versions of drugs such as glyburide, quetiapine fumarate ER, and metoprolol succinate ER, and offers co-development, marketing partnerships, dossier development, technology transfer, and contract development and manufacturing services. | Health Technology |
PharmaDax (Guangzhou), Inc. | |
Sandex Group Ltd. | |
Fortune Tower Group Corp. | |
Empax Pharma (Foshan) Inc. | |
Shengqun Pharmaceutical Co., Ltd. |
